Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : SNYNF save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $41.14 -2.49% -2.55% 280K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
Published: 2024-01-09 (Crawled : 22:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
drug companies achondroplasia positive treatment key therapeutics growth market
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
Published: 2023-12-15 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
first positive treatment ema africa
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published: 2023-12-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
UCBJY | $64.535 -4.38% 3.5K
|
Manufacturing
|
| O: -0.62%
H: 1.01%
C: 1.01%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
CPRX | News | $15.11 -0.13% -0.13% 1M
|
Health Technology
|
| O: -0.37%
H: 5.49%
C: 5.49%
companies positive growth study market
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
positive ongoing collaboration study
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
dupixent positive copd results sanofi
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Players - MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics
Published: 2023-10-30 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
ALPMY | News | $9.5 -1.11% 1M
|
Manufacturing
|
| O: -1.67%
H: 3.16%
C: 2.75%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
positive treatment growth market
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
disease alzheimer’s positive results
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 15:30) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -2.24%
H: 7.12%
C: 4.11%
bnt211 candidate congress tumors positive update cell car-t therapy
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
Published: 2023-10-11 (Crawled : 14:00) - globenewswire.com
MLTX | $41.14 -2.49% -2.55% 280K
|
|
| O: 1.63%
H: 1.95%
C: -8.55%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
nanobody congress positive trial
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published: 2023-10-04 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
MRNA | News S | $104.48 3.03% 2.94% 3.1M
|
Health Technology
|
| O: 1.48%
H: 0.2%
C: -0.33%
rna-1083 covid-19 vaccine positive influenza
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: -0.15%
H: 1.32%
C: -0.02%
positive treat risk topline hypertension cardiovascular results study
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Published: 2023-08-30 (Crawled : 14:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
covid-19 chmp vaccine positive
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $145.78 0.95% 0.94% 390K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.